Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | ESR1 | P03372 | 4/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8598884 | 0.92 | CYP3A4 (0.67) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL18832826 | 0.92 | CYP3A4 (0.67) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL2387556 | 0.84 | TDP1 (0.86) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL101 | 0.84 | TDP1 (1.00) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL2085135 | 0.84 | TDP1 (1.00) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL5028587 | 0.84 | TDP1 (1.00) | CYP3A4TDP1ESR1ESR2KDM4E | |
| Benzene SCHEMBL6890099 | 0.84 | TDP1 (1.00) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL19022528 | 0.81 | TDP1 (0.80) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL21296015 | 0.81 | TDP1 (0.80) | CYP3A4TDP1ESR1ESR2KDM4E | |
| SCHEMBL30213620 | 0.81 | TDP1 (0.80) | CYP3A4TDP1ESR1ESR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378428-B2 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-27 | — | — | US | disclosed |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
| EP-1008601-A2 | Method for producing palladium complex compound | Central Glass Company, Limited (JP) | 2000-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | PARK7, MMP8, CDK7 | CYP3A4 1813/4885TDP1 2161/4885ESR1 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.